delgocitinib

Absorption: Systemic absorption occurs following topical administration.

Distribution: Unknown.

Metabolism/Excretion: Does not undergo extensive metabolism. Primarily excreted in the urine as unchanged drug (75%).

Half-Life: 21 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
Top	unknown	unknown	unknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Active, serious infection.

Use Cautiously in:

Chronic or recurrent infection;
Exposure to tuberculosis;
History of a serious infection or opportunistic infection;
Underlying condition that predisposes to infection;
>50 yr old with ≥1 cardiovascular risk factor (may ↑ risk of all-cause mortality, cardiovascular death, MI, stroke, and thrombosis);
OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: bacterial skin infection, erythema, NONMELANOMA SKIN CANCER, pruritus

Hemat: leukopenia, neutropenia

Local: application site pain

Neuro: paresthesia

Misc: infection (including viral reactivation)

Interactions ⬆ ⬇

Drug-drug:

May ↑ risk of adverse reactions and ↓ antibody response to live vaccines; avoid concurrent use.

Route/Dosage ⬆ ⬇

(Adults ): Apply a thin layer twice daily to affected areas only on the hands and wrists. Do not use more than one 30-g tube per 2 wk or one 60-g tube per mo.

Availability ⬆ ⬇

Assessment ⬆ ⬇

Ensure completion of all necessary immunizations, including herpes zoster vaccination, in accordance with current guidelines before treatment.
Assess skin at application sites periodically for lesions or changes suggestive of nonmelanoma skin cancer.
Monitor for signs/symptoms of infection during and after treatment. If a new infection occurs, complete diagnostic testing, start appropriate antimicrobial therapy, and monitor patient closely. Discontinue delgocitinib if a serious infection develops and do not resume until resolution or adequately treated.

Lab Test Considerations:

May ↑ total cholesterol, LDL-C, and triglycerides.
Screen and monitor for viral hepatitis reactivation in accordance with current clinical guidelines before and during treatment.

Implementation ⬆ ⬇

Topical Clean and dry affected areas before applying. Apply a thin layer twice daily to affected areas only on the hands and wrists.

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Advise patient on proper administration.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care provider before taking other medications.
Advise patient that delgocitinib may ↓ the ability of the immune system to fight infections and to notify health care provider immediately if any signs/symptoms of infection develop.
Advise patient to avoid contact with eyes, mouth, or other mucous membranes. If contact with mucous membranes occurs, rinse thoroughly with water.
Advise patient to avoid live vaccines immediately before, during, and immediately after treatment.
Advise patient to have periodic skin examinations due to the ↑ risk of developing nonmelanoma skin cancers. Advise patient to notify health care provider of any prior cancer diagnoses. Advise patient to avoid sunlamps and minimize exposure to sunlight by wearing sun-protective clothing or using broad-spectrum sunscreen.
Rep: Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Advise breastfeeding patients to avoid direct contact with the nipple and surrounding area immediately after applying delgocitinib to the hands and/or wrists.

Evaluation/Desired Outcomes ⬆ ⬇

Decreased severity of chronic hand eczema.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

50222- LEO Pharma, Inc
- 50222-280- Anzupgo
  - 50222-280-30- 1 TUBE in 1 CARTON (50222-280-30) / 30 g in 1 TUBE

50222- LEO Pharma, Inc
- 50222-280- Anzupgo
  - 50222-280-91- 1 TUBE in 1 CARTON (50222-280-91) / 15 g in 1 TUBE

50222- LEO Pharma, Inc
- 50222-280- Anzupgo
  - 50222-280-99- 1 TUBE in 1 CARTON (50222-280-99) / 5 g in 1 TUBE

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇